Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
/in Dendritic Cells, International Publications /von 2015-10-20 / Oncotarget 2015 Oct;6(32):33781-90Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy
/in Dendritic Cells, Hyperthermia, International Publications /von 2015-10-15 / BMC Cancer 2015 Oct;15:708Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
/in IOZK Veröffentlichungen /von IOZKValidity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients
/in Colorectal Cancer, International Publications /von 2015-10-09 / Cytotherapy 2015 Dec;17(12):1746-62Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71Immunotherapy for hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-71Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6Natural and therapy-induced immunosurveillance in breast cancer
/in Breast Cancer, International Publications /von 2015-10-01 / Nat. Med. 2015 Oct;21(10):1128-38Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-10-01 / J. Immunother. 2015 Oct;38(8):330-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution